A milestone in breast cancer treatment was the first HER2-targeted therapeutic monoclonal antibody, named trastuzumab (trade name, Herceptin ®), approved by the FDA for treatment of HER2-positive breast cancer (Tolaney et al., 2015). The gene discussed is ERBB2; the disease is breast carcinoma.